DMPI: Ready to advance VAL-083 to pivotal Phase II/III trial in 1H2016, pipeline will be expanded to include NSCLC and ovarian cancer Buy
DelMar Pharmaceuticals is a clinical stage drug development company with a focus on the treatment of cancer. Co.'s primary product candidate, VAL-083, is a small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of a product approved, or in development for the treatment of cancer. VAL-083 is also a DNA-targeting agent. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer. VAL-083 has not been approved for any indications outside of China. Co. is studying VAL-083 in clinical trials for the treatment of glioblastoma multiforme, which is a form of brain cancer.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.